EA202091978A1 - SPECIFIC BINDING AGENTS AND THEIR APPLICATIONS - Google Patents

SPECIFIC BINDING AGENTS AND THEIR APPLICATIONS

Info

Publication number
EA202091978A1
EA202091978A1 EA202091978A EA202091978A EA202091978A1 EA 202091978 A1 EA202091978 A1 EA 202091978A1 EA 202091978 A EA202091978 A EA 202091978A EA 202091978 A EA202091978 A EA 202091978A EA 202091978 A1 EA202091978 A1 EA 202091978A1
Authority
EA
Eurasian Patent Office
Prior art keywords
binding agents
applications
specific binding
agents
methods
Prior art date
Application number
EA202091978A
Other languages
Russian (ru)
Inventor
Стивен Ларсон
Най-Кун В. Чун
Сара Чил
Original Assignee
Мемориал Слоун Кеттеринг Кэнсер Сентр
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мемориал Слоун Кеттеринг Кэнсер Сентр filed Critical Мемориал Слоун Кеттеринг Кэнсер Сентр
Priority claimed from PCT/US2019/021612 external-priority patent/WO2019177970A1/en
Publication of EA202091978A1 publication Critical patent/EA202091978A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Согласно настоящему изобретению предложены композиции, способы и варианты применения, включающие (i) биспецифические связывающие агенты, которые специфически связываются с раковым антигеном, (ii) агенты для выведения и (iii) радиотерапевтические агенты для лечения рака. Также согласно настоящему изобретению предложены варианты применения и способы лечения связанных с HER2 видов рака.The present invention provides compositions, methods, and uses comprising (i) bispecific binding agents that specifically bind to a cancer antigen, (ii) agents for excretion, and (iii) radiotherapeutic agents for treating cancer. The present invention also provides uses and methods for treating HER2-associated cancers.

EA202091978A 2019-03-04 2019-03-11 SPECIFIC BINDING AGENTS AND THEIR APPLICATIONS EA202091978A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962813592P 2019-03-04 2019-03-04
PCT/US2019/021612 WO2019177970A1 (en) 2018-03-12 2019-03-11 Bispecific binding agents and uses thereof

Publications (1)

Publication Number Publication Date
EA202091978A1 true EA202091978A1 (en) 2021-02-16

Family

ID=74855449

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091978A EA202091978A1 (en) 2019-03-04 2019-03-11 SPECIFIC BINDING AGENTS AND THEIR APPLICATIONS

Country Status (1)

Country Link
EA (1) EA202091978A1 (en)

Similar Documents

Publication Publication Date Title
EA201992526A1 (en) STABILITIES OF ANTI-CTLA4 ANTIBODIES, SEPARATELY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF APPLICATION
EA201891909A1 (en) TGFβ1-BINDING IMMUNOGLOBULINS AND THEIR APPLICATION
MX2019009967A (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof.
EA201792184A1 (en) ANTIBODIES DIRECTED AGAINST T-CELL IMMUNOGLOBULIN AND MUTIN PROTEIN 3 (TIM-3)
EA201892362A1 (en) AGONISTIC ANTIBODIES THAT ARE BINDING HUMAN CD40, AND THEIR OPTIONS
EA201891428A1 (en) COMBINATION OF ANTIBODIES TO PD-1 AND BISPECIFIC ANTIBODIES TO CD20 / CD3 FOR THE TREATMENT OF MALIGNANT TUMOR
CR20120454A (en) THERAPEUTIC PROTEINS OF DLL4 UNION
MX2015015037A (en) Antibodies directed against programmed death-1 (pd-1).
MX2021007939A (en) Claudin18.2 binding moieties and uses thereof.
PH12021551500A1 (en) Anti-ctla4 antibodies and methods of use thereof
EA201992318A1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSTIC AND TREATMENT OF PROSTATE CANCER USING A MOLECULE BINDING PROGASTRIN
MX2021005048A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof.
PH12019550233A1 (en) A novel anti-c-met antibody and use thereof
MX2020010104A (en) Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates.
EA201992315A1 (en) COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER
PH12020551187A1 (en) Bispecific antigen-binding molecules and methods of use
MX2021006362A (en) Single domain antibodies against cll-1.
EA201891529A1 (en) COMPOSITIONS AND METHODS OF DETECTION AND TREATMENT OF OVARIAN CANCER
PE20231573A1 (en) CD47-CD38 BISPECIFIC ANTIBODIES
CR20220061A (en) Antibodies which bind to cancer cells and target radionuclides to said cells
EA201892096A1 (en) NEUTRALIZING MONOCLONAL ANTIBODIES TO IL-25 AND THEIR APPLICATION
BR112021020873A2 (en) Methods for treating kidney cancer with an anti-psma/cd3 antibody
EA202091978A1 (en) SPECIFIC BINDING AGENTS AND THEIR APPLICATIONS
MX2022001882A (en) 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40.
ECSP21028958A (en) MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO CD20 ANTIGEN